AGCT1532 - Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours

Go Back to All Clinical Trials

AGCT1532 - Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours

Brief description of study

The purpose of this study is to investigate the accelerated BEP in improving the safety and efficacy for patients with intermediate and poor-risk metastatic germ cell tumours. We want to know if accelerated BEP is superior to standard BEP.

We are using study drugs Ifosfamide, Cisplatin, Pegfilgrastim, Etoposide, Bleomycin, MESNA and Filgrastim to determine progression- free survival, adverse events, and health-related quality of life.

Clinical Study Identifier: s22-00117

ClinicalTrials.gov Identifier: NCT02582697

Principal Investigator: Sharon L Gardner.

Other Investigators: Ashley Pinchinat, Nicole Mallory, William L Carroll, Jessica Clymer, Elizabeth Ann Roman, Elizabeth A Raetz, Gabriel Andrew Robbins, Kirsty Hillier.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies